U.S. By

How Lilly's Retatrutide Compared With Ozempic in a Head-to-Head Diabetes Trial

Eli Lilly said on Oct. 28 that its experimental drug retatrutide lowered blood sugar more and produced far greater weight loss than Ozempic at the highest approved dose in a Phase 3 trial of adults with type 2 diabetes. The drug is not approved anywhere, and the full data have not yet been peer-reviewed or published.

The results come from a trial called TRANSCEND-T2D-2, which Lilly announced in a press release. Business Insider reported that the company plans to submit retatrutide to the Food and Drug Administration in early 2027.

What did the trial find?

The study compared once-weekly retatrutide at two doses with Ozempic 2 mg, the highest approved dose, over 80 weeks. According to Lilly, retatrutide met its primary goal and all key secondary goals.

Both retatrutide doses lowered A1C, a measure of blood sugar control, by an average of 2.2%, compared with 1.8% for Ozempic. Lilly said retatrutide also improved some cardiovascular risk factors more than Ozempic did, including non-HDL cholesterol, triglycerides and systolic blood pressure.

How much weight did participants lose?

Lilly reported that people on retatrutide lost an average of 44.3 lbs (19.5%) at the 9 mg dose and 47.4 lbs (20.9%) at the 12 mg dose. Those on Ozempic lost an average of 20.9 lbs (9.4%).

STAT News, as relayed by UA.News, noted that the weight figures reflect participants who stayed on treatment, not everyone who enrolled. Lilly also said that in a separate trial, TRIUMPH-2, people with type 2 diabetes and obesity on the highest retatrutide dose lost an average of 49.6 lbs (20.8%).

What about side effects?

Lilly said the most common side effects were digestive. Diarrhea affected 28.3% of patients on the 9 mg dose and 32.7% on the 12 mg dose, versus 26.4% on Ozempic. Nausea was about the same across groups. Constipation was somewhat less common with retatrutide.

Dysesthesia, an abnormal skin sensation that Business Insider described as tingling or burning, occurred in 4.8% and 6.5% of retatrutide patients, versus 2.7% on Ozempic. Lilly said most side effects were mild to moderate and typically resolved during treatment.

More retatrutide patients stopped treatment because of side effects: 4.8% at 9 mg and 7.9% at 12 mg, compared with 2.7% for Ozempic.

What does this mean for people with type 2 diabetes?

For now, nothing changes in what patients can be prescribed. Retatrutide has not been approved by the FDA or any other regulator, and Lilly says it cannot legally be sold or marketed for human use.

Lilly argues that weight loss has historically been harder for people with type 2 diabetes, and that head-to-head trials show how a new drug compares with treatments already available. Kenneth Custer, who leads Lilly's cardiometabolic business, said the company believes retatrutide could change how type 2 diabetes, obesity and related conditions are treated if it is approved. That is the company's view, based on its own announcement of topline results.

Business Insider reported that, if all goes well, the drug could reach the market sometime next year for conditions including obesity, obesity-related sleep apnea and knee osteoarthritis.

Why does the black market for retatrutide come up?

Business Insider reported that sellers overseas are already shipping powders labeled as retatrutide, feeding a gray market of do-it-yourself injections. The outlet said buyers cannot be sure what they are taking.

Lilly took the unusual step of addressing this in its release. The company said anyone claiming to sell retatrutide to consumers is breaking the law.

What happens next?

Lilly said detailed results will be presented at a future medical meeting and published in a peer-reviewed journal. The company is also running TRIUMPH-5, an ongoing Phase 3 trial comparing retatrutide directly with tirzepatide, the drug in Lilly's Mounjaro, in adults with obesity, with or without type 2 diabetes.

Business Insider noted that Lilly released the results as it prepares to report quarterly earnings on Thursday. TRANSCEND-T2D-2 is the sixth Phase 3 trial in which Lilly says retatrutide has shown strong results.

Around Prague, based on reporting by PR Newswire, Business Insider, UA.NEWS

Share: Telegram WhatsApp

More U.S. news

Robert Garcia Orders Trump Allies to Save Records Ahead of House Probes
Rep. Robert Garcia, the top Democrat on the House Oversight Committee, sent letters Wednesday telling a dozen or more associates of President Donald Trump to preserve their records before Democrats ta
Iran Targets Kuwait and Bahrain After U.S. Strike on Missile Site
Iran's army said its drones targeted U.S. military assets at Ali Al Salem Air Base in Kuwait, and Bahrain reported intercepting multiple Iranian aerial attacks, as a months-long confrontation in the G
Ransomware Gang Claims Nvidia Hack and Starts a 10-Day Countdown, but Shows No Proof
The Gentlemen, one of the most active ransomware groups of the past year, has added Nvidia to its dark web leak site and started a countdown to publish what it says is the chipmaker's data. The group
What Florida's Coastal Flooding Means for Residents and Thanksgiving Travelers
Floodwater closed roads, stranded vehicles and entered homes in southeast Florida on Tuesday night, CNN reported, as the first stretch of a multiday flood threat began along the state's Atlantic coast
Hakeem Jeffries Wins House Democrats' Nomination for Speaker, 251-11
House Democrats on Wednesday nominated Rep. Hakeem Jeffries of New York to be speaker of the House, a step that puts him on track to become the first Black speaker in U.S. history when the new Congres
What Target's Strong Quarter Means for Holiday Shoppers and Prices
Target said Wednesday that its net sales grew at the fastest pace in roughly five years in the third quarter, helped by price cuts, expanded same-day delivery and a refreshed product lineup. The compa

Related news

Rep. Robert Garcia, the top Democrat on the House Oversight Committee, sent letters Wednesday telling a dozen or more associates of President Donald Trump to preserve their records before Democrats take control of the House in January. NBC
Iran's army said its drones targeted U.S. military assets at Ali Al Salem Air Base in Kuwait, and Bahrain reported intercepting multiple Iranian aerial attacks, as a months-long confrontation in the Gulf flared again, according to Fox News
The Gentlemen, one of the most active ransomware groups of the past year, has added Nvidia to its dark web leak site and started a countdown to publish what it says is the chipmaker's data. The group has not shown any stolen files, and Nvid
Floodwater closed roads, stranded vehicles and entered homes in southeast Florida on Tuesday night, CNN reported, as the first stretch of a multiday flood threat began along the state's Atlantic coast. More heavy rain is forecast through Fr
House Democrats on Wednesday nominated Rep. Hakeem Jeffries of New York to be speaker of the House, a step that puts him on track to become the first Black speaker in U.S. history when the new Congress convenes. The vote was 251 to 11, acco
Target said Wednesday that its net sales grew at the fastest pace in roughly five years in the third quarter, helped by price cuts, expanded same-day delivery and a refreshed product lineup. The company raised its full-year sales and earnin
The United States has lost its measles elimination status, ending a run that began in 2000. The Pan American Health Organization (PAHO) announced the decision on Tuesday, according to Fox News and The Guardian, as the country deals with its
Los Angeles County health officials have ordered the operator of the Chiquita Canyon Landfill to pay for relief for nearby residents, including short-term hotel stays, after a drilling problem sent a geyser of trash and gas into the air, NB
Players waiting for "Grand Theft Auto 6" on PS5 and Xbox Series X|S can expect it to unlock at midnight local time on Nov. 19, according to Rockstar support, as relayed by PC Gamer. That means a rolling launch, not one global start time. Th
Director of National Intelligence Jay Clayton said Tuesday that technical problems hitting the National Security Agency and other organizations are not the result of a cyberattack or state-sponsored activity, according to ABC News. Secretar
Democrat Mary Peltola has defeated Republican Sen. Dan Sullivan in Alaska, according to Roll Call, NBC News and The Guardian. The Associated Press called the race Tuesday night, two weeks after Election Day. The win gives Democrats 56 seats
The White House has dropped Dr. Heidi Overton's nomination to lead the Food and Drug Administration, a White House official confirmed Tuesday, according to NBC News and CNN. The Senate health committee had been due to vote on her Wednesday.